GNS.L

Genus Plc
Genus - Chief Financial Officer Retirement
22nd October 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0155J
Genus PLC
22 October 2024
 

22 October 2024

 

Genus plc

Chief Financial Officer Retirement

("Genus" or the "Group")

 

Genus (LSE: GNS), a leading global animal genetics company, announces that Alison Henriksen,  Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement.

The Board has initiated a comprehensive search for Alison's successor and will provide an update once this process has concluded.

Jorgen Kokke, Group Chief Executive Officer, commented:

"On behalf of the Board, I would like to thank Alison for her support and significant contribution to Genus's development over the last five years. Alison's financial leadership has been instrumental in Genus building a strong growth platform for many years to come. On a personal note, it has been a pleasure working with Alison, and I'm appreciative of her partnership since I joined Genus, however I fully understand her desire to create more time for family, her other interests, and to return to Australia."    

 

For further information please contact:

Genus plc            Tel: +44 125 634 5970

Jorgen Kokke, Chief Executive Officer

Alison Henriksen, Chief Financial Officer

Anand Date, Investor Relations Director

Buchanan            Tel: +44 207 466 5000

Charles Ryland; Toto Berger; Sophie Wills; Verity Parker

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

Regulatory notes

Details of Alison's terms of departure will be consistent with Genus's existing remuneration policy and the terms will be posted on the Company's website, in accordance with section 430(2B) Companies Act 2006.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAKEFAENLFFA]]>
TwitterFacebookLinkedIn